(Q46511557)

22 December 2017

title

Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials (English)

1 reference

22 December 2017

0 references

1 reference

cytomegaloviral disease

1 reference

L Demopoulos

1

1 reference

22 December 2017

M Polinsky

2

1 reference

22 December 2017

G Steele

3

1 reference

22 December 2017

D Mines

4

1 reference

22 December 2017

M Blum

5

1 reference

22 December 2017

M Caulfield

6

1 reference

22 December 2017

A Adamkovic

7

1 reference

22 December 2017

Q Liu

8

1 reference

22 December 2017

M B Harler

9

1 reference

22 December 2017

C Hahn

10

1 reference

22 December 2017

A Singh

11

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

22 December 2017

Transplantation Proceedings

published in

1 reference

22 December 2017

volume

40

1 reference

22 December 2017

issue

5

1 reference

22 December 2017

page(s)

1407-1410

1 reference

22 December 2017

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

Seroprevalence of cytomegalovirus infection in the United States, 1988-1994

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

Reduced exposure to calcineurin inhibitors in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.03.084

10.1016/J.TRANSPROCEED.2008.03.084

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017